Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sionna Therapeutics Inc (SION)

Sionna Therapeutics Inc (SION)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,751,688
  • Shares Outstanding, K 44,629
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,690 K
  • EBIT $ -84 M
  • EBITDA $ -86 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.61
  • Number of Estimates 3
  • High Estimate -0.47
  • Low Estimate -0.71
  • Prior Year -3.38
  • Growth Rate Est. (year over year) +81.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.95 +9.18%
on 01/08/26
45.00 -12.78%
on 12/29/25
-2.34 (-5.63%)
since 12/09/25
3-Month
27.72 +41.59%
on 10/10/25
45.00 -12.78%
on 12/29/25
+10.90 (+38.45%)
since 10/09/25

Most Recent Stories

More News
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...

SION : 39.25 (+7.24%)
Stocks Retreat as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down by -0.53%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.90%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.36%....

MSTR : 157.33 (-5.77%)
MPC : 176.17 (-0.51%)
GLXY : 24.94 (-2.20%)
LVS : 58.95 (-4.77%)
WYNN : 117.83 (-0.37%)
$IUXX : 25,766.26 (+1.02%)
COIN : 240.78 (-1.96%)
ZNH26 : 112-070s (-0.03%)
SHOP : 164.48 (-2.26%)
SION : 39.25 (+7.24%)
ESH26 : 7,005.00s (+0.62%)
FANG : 147.41 (-0.17%)
Stocks Fall as Rising Bond Yields Spark Risk-Off Sentiment

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.29%. December E-mini...

MSTR : 157.33 (-5.77%)
MPC : 176.17 (-0.51%)
CVX : 162.11 (+1.80%)
GLXY : 24.94 (-2.20%)
LVS : 58.95 (-4.77%)
WYNN : 117.83 (-0.37%)
$IUXX : 25,766.26 (+1.02%)
COIN : 240.78 (-1.96%)
ZNH26 : 112-070s (-0.03%)
SHOP : 164.48 (-2.26%)
OXY : 42.86 (-0.86%)
SION : 39.25 (+7.24%)
Stocks Pressured by Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.59%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.97%. December E-mini...

MSTR : 157.33 (-5.77%)
MPC : 176.17 (-0.51%)
CVX : 162.11 (+1.80%)
GLXY : 24.94 (-2.20%)
LVS : 58.95 (-4.77%)
WYNN : 117.83 (-0.37%)
$IUXX : 25,766.26 (+1.02%)
COIN : 240.78 (-1.96%)
ZNH26 : 112-070s (-0.03%)
SHOP : 164.48 (-2.26%)
OXY : 42.86 (-0.86%)
SION : 39.25 (+7.24%)
Sionna Therapeutics to Participate in Upcoming December Investor Conferences

WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...

SION : 39.25 (+7.24%)
Sionna Therapeutics Reports Third Quarter 2025 Financial Results

Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Successfully completed drug-drug interaction...

SION : 39.25 (+7.24%)
Sionna Therapeutics to Participate in Upcoming November Investor Conferences

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...

SION : 39.25 (+7.24%)
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that...

SION : 39.25 (+7.24%)
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics,...

SION : 39.25 (+7.24%)
Sionna Therapeutics, Inc. (SION) Gets a Buy from Raymond James

Raymond James analyst maintained a Buy rating on Sionna Therapeutics, Inc. today and set a price target of $45.00. The company’s shares closed yesterday at $30.91.Elevate Your Investing Strategy: Take...

SION : 39.25 (+7.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sionna Therapeutics Inc. is a clinical-stage biopharmaceutical company by developing novel medicines that normalize the function of the CFTR protein. Sionna Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 43.28
2nd Resistance Point 41.49
1st Resistance Point 40.37
Last Price 39.25
1st Support Level 37.46
2nd Support Level 35.67
3rd Support Level 34.55

See More

52-Week High 45.00
Last Price 39.25
Fibonacci 61.8% 30.58
Fibonacci 50% 26.13
Fibonacci 38.2% 21.67
52-Week Low 7.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar